Dry Eye Syndromes Clinical Trial
Official title:
A Phase II, Multicentre, Randomised, Placebo-controlled, Doublemasked Trial of RP101 Ophthalmic Formulation Versus Vehicle in Post-menopausal Women With Moderate to Severe Dry Eye Syndrome
The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.
Redwood Pharma is developing the novel ophthalmic product RP101 containing the known active
substance 17β-oestradiol-3-phosphate and based upon the drug delivery platform IntelliGel
which controls the active substance release. The novel formulation is planned to meet the
still unmet medical need of an efficacious treatment against chronic dry eye in
postmenopausal women.
The efficacy of the novel formulation RP101 will be investigated for the first time in the
present multicentre, randomised, double-masked, parallel-group, placebo-controlled Phase II
study in women post-menopausal for at least 3 years presenting with symptoms specific for dry
eye syndrome of moderate to severe intensity.
The planned study will be conducted in Austria, Germany and Hungary. The primary objective of
the study is to establish the effective dose/dose regimen of RP101 in these patients applying
RP101 ophthalmic sterile solution or matching placebo (vehicle) once (q.d.) or twice a day
(b.i.d.) for 3 months. One hundred (100) patients will be enrolled in this study. The
subjects will be randomly assigned (1:1:1:1) to a treatment group and will receive one of the
treatments for 90 consecutive days.
Evaluation of the clinical efficacy during and at the end of the treatment will be done on
the basis of the Schirmer's test type II (with anaesthesia).
The secondary objectives of the study are:
- to evaluate the safety and tolerability of the treatment
- to evaluate the pharmacokinetics (PK) of serum 17β-oestradiol after the 1st and the last
dose (only PK substudy).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
| Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
| Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
| Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
| Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
| Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
| Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
| Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
| Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
| Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
| Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
| Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
| Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
| Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
| Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
| Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
| Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
| Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
| Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
| Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |